Estrella Immunopharma FY26 Q2 net loss narrows 58.18% to $2.3 million
ESLA•Six-month loss also declines
For the six months ended June 30, 2026, net loss narrowed to USD 4.6 million from USD 7.6 million as R&D declined 53.9% to USD 2.8 million.
Cash position and accrued liability
Cash and cash equivalents totaled USD 115,000 at June 30, 2026, with an USD 8.3 million accrued liability tied to STARLIGHT-1 dosing milestones.
Second-quarter loss narrows as expenses fall
Estrella Immunopharma posted a GAAP net loss of USD 2.3 million for the three months ended June 30, 2026, narrowing from USD 5.5 million.
Research and development expense fell 69.9% to USD 1.4 million on timing of patient dosing milestones payable to Eureka.
General and administrative costs dropped 22.6% to USD 0.7 million on lower legal and professional fees.
